Skip to main content
SpringerLink
Log in

Overview of Hematopoietic Cell Transplantation

  • Chapter
  • First Online:
Atlas of Graft-versus-Host Disease

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a form of immune therapy used to treat a variety of malignant and nonmalignant diseases. The procedure involves transfusion of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood from a donor, usually matched in human leukocyte antigens (HLA). Immediately prior to HSCT, patients receive conditioning chemoradiotherapy to eliminate underlying hematologic malignant cells, and to sufficiently suppress the host’s immune functions for successful engraftment of donor hematopoietic cells. Following the conditioning regimen and HSCT, donor-derived hematopoietic recovery and immune reconstitution occur, during which patients require intensive supportive care, including prevention and treatment of complications such as infections and acute or chronic graft-versus-host disease (GVHD).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2015. Available at: http://www.cibmtr.org.

    Google Scholar 

  2. Jacobson LO, Marks EK, Gaston EO, et al. The role of the spleen in radiation injury. Proc Soc Exp Biol Med. 1949;70:740–2.

    Article  CAS  PubMed  Google Scholar 

  3. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956;2(4993):626–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49:511–33.

    CAS  PubMed  Google Scholar 

  5. Blume KG, Beutler E. Allogeneic bone marrow transplantation for acute leukemia. JAMA. 1979;241:1686.

    Article  CAS  PubMed  Google Scholar 

  6. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–35.

    Article  CAS  PubMed  Google Scholar 

  7. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729–34.

    CAS  PubMed  Google Scholar 

  8. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112:903–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–11.

    Article  CAS  PubMed  Google Scholar 

  10. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345:1794–800.

    Article  CAS  PubMed  Google Scholar 

  11. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–54.

    CAS  PubMed  Google Scholar 

  12. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001;27(Suppl 2):S13–22.

    Article  PubMed  Google Scholar 

  13. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 5th ed. Hoboken: Wiley; 2016. p. 8–17.

    Chapter  Google Scholar 

  14. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.

    Article  CAS  PubMed  Google Scholar 

  16. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537–46.

    CAS  PubMed  Google Scholar 

  17. Faucher C, Mohty M, Vey N, Gaugler B, Bilger K, Moziconnacci MJ, et al. Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Exp Hematol. 2003;31:873–80.

    Article  PubMed  Google Scholar 

  18. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98:2900–8.

    Article  CAS  PubMed  Google Scholar 

  19. Körbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86:2842–8.

    PubMed  Google Scholar 

  20. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. European Group for Blood and Marrow Transplantation. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–7.

    Article  CAS  PubMed  Google Scholar 

  21. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–7.

    Article  CAS  PubMed  Google Scholar 

  22. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815–22.

    Article  CAS  PubMed  Google Scholar 

  23. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.

    Article  CAS  PubMed  Google Scholar 

  24. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.

    Article  CAS  PubMed  Google Scholar 

  26. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.

    Article  CAS  PubMed  Google Scholar 

  27. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.

    Article  PubMed  Google Scholar 

  28. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119:3908–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500.

    Article  CAS  PubMed  Google Scholar 

  30. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010;3:36.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367:135–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004;101:3921–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30:3202–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53:90–7.

    Article  PubMed  Google Scholar 

  36. Kekre N, Antin JH. Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol. 2016;53:98–102.

    Article  PubMed  Google Scholar 

  37. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014;124:3221–3227; quiz 3335.

    Google Scholar 

  38. Reinherz EL, Parkman R, Rappeport J, Rosen FS, Schlossman SF. Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med. 1979;300:1061–8.

    Article  CAS  PubMed  Google Scholar 

  39. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461–6.

    Article  CAS  PubMed  Google Scholar 

  40. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134–41.

    Google Scholar 

  41. Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51:43–50.

    Article  CAS  PubMed  Google Scholar 

  42. van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16:1423–31.

    Article  PubMed  Google Scholar 

  44. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36:528–38.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767–76.

    Article  CAS  PubMed  Google Scholar 

  46. MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol. 2000;110:12–7.

    Article  CAS  PubMed  Google Scholar 

  47. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125:435–54.

    Article  PubMed  Google Scholar 

  48. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–96.

    Article  PubMed  Google Scholar 

  49. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA

    Amandeep Salhotra

  2. Division of Dermatology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA

    Ryotaro Nakamura

Authors
  1. Amandeep Salhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryotaro Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amandeep Salhotra .

Editor information

Editors and Affiliations

  1. Division of Dermatology, City of Hope National Medical Center Division of Dermatology, Durante, California, USA

    Jonathan A. Cotliar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Salhotra, A., Nakamura, R. (2017). Overview of Hematopoietic Cell Transplantation. In: Cotliar, J. (eds) Atlas of Graft-versus-Host Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-46952-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46952-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46950-8

  • Online ISBN: 978-3-319-46952-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation